Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions

Roxane Laboratories28 enrolled

Overview

The objective of this study was to assess the bioequivalence of a potential generic 600 mg oxcarbazepine tablet formulation with Novartis Pharmaceutical's 600 mg oxcarbazepine tablet, Trileptal, folloiwng a single 600 mg dose administered with food.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Epilepsy Seizures

Interventions

OxcarbazepineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 45 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * No clinically significant abnormal finding on the physical examination, medical history, or clinical laboratory results during screening. Exclusion Criteria: * Positive test for HIV, Hepatitis B, or Hepatitis C. * Treatment with known enzyme altering drugs. * History of allergic or advers response to oxcarbazepine or any other comparable or similar product.

Locations (1)

MDS Pharma Services

Montreal, Quebec, Canada

Outcomes

Primary Outcomes

Bioequivalence

Time frame: Baseline, two period, 7 day washout

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.